Filament Health Corp (FH) - Total Liabilities
Based on the latest financial reports, Filament Health Corp (FH) has total liabilities worth CA$1.94 Million CAD (≈ $1.40 Million USD) as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Filament Health Corp annual equity growth to track the company's year-over-year net asset growth rate.
Filament Health Corp - Total Liabilities Trend (2020–2024)
This chart illustrates how Filament Health Corp's total liabilities have evolved over time, based on quarterly financial data. See Filament Health Corp free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Filament Health Corp Competitors by Total Liabilities
The table below lists competitors of Filament Health Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Starbreeze AB (publ)
ST:STAR-A
|
Sweden | Skr116.45 Million |
|
Baiya International Group Inc. Ordinary Shares
NASDAQ:BIYA
|
USA | $4.40 Million |
|
DMC Mining Ltd
AU:DMM
|
Australia | AU$1.55 Million |
|
Redcentric
LSE:RCN
|
UK | GBX125.64 Million |
|
Kore Potash Plc
LSE:KP2
|
UK | GBX2.74 Million |
|
Direct Digital Holdings Inc
NASDAQ:DRCT
|
USA | $28.98 Million |
|
BT Wealth Industries Public Company Limited
BK:BTW
|
Thailand | ฿443.67 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down Filament Health Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see FH stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.99 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.67 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Filament Health Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Filament Health Corp (2020–2024)
The table below shows the annual total liabilities of Filament Health Corp from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CA$1.66 Million ≈ $1.20 Million |
-46.02% |
| 2023-12-31 | CA$3.08 Million ≈ $2.23 Million |
+99.35% |
| 2022-12-31 | CA$1.55 Million ≈ $1.12 Million |
+19.99% |
| 2021-12-31 | CA$1.29 Million ≈ $932.83K |
+1798.69% |
| 2020-12-31 | CA$67.92K ≈ $49.13K |
-- |
About Filament Health Corp
Filament Health Corp. operates as a clinical-stage natural psychedelic drug development company in Canada. The company's leading drug candidates comprises PEX010 oral psilocybin, PEX020 oral psilocin, and PEX030 sublingual psilocin. It also develops AEX010 ayahuasca, which is in preclinical stage; and AEX020 monoamine oxidase inhibitor and is in preclinical stage. In addition, the company provide… Read more